Europe Human Microbiome Market to 2025 - Regional Analysis and Forecasts by Product (Probiotics, Foods, Prebiotics, Medical Foods, Diagnostic Device, Drugs, and Supplements), Disease (Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders, and Others), Application (Therapeutics and Diagnostics), and Country
Publication Month: Feb 2019
Report Code: TIPRE00003318 No. of Pages: 149 Category: Biotechnology Status: Published
The Europe human microbiome market is expected to reach US$ 346.67 Mn in 2025 from US$ 72.34 in 2017. The market is estimated to grow with a CAGR of 22.2% from 2018-2025.
The growth of the market is driven by the factors such alarming rise in non-communicable diseases (NCDS), rising efforts in the development of human microbiome based therapies and developments in genomics and sequencing techniques. Whereas, rigorous government regulations for advanced therapies and limited understanding is likely to have a negative impact on the growth of the market in the coming years.
Fecal microbiota transplantation (FMT) has developed as an effective treatment for C. difficile infection (CDI) refractory towards antibiotic therapy. The microbiota have important roles in the function of gastrointestinal tract and other aspects of human physiology, there is also growing interest in studying FMT for other clinical indications. The US Food and Drug Administration (FDA) has classified human stool as a biological agent and determined that its use in fecal microbiota transplantation (FMT) therapy and other research are regulated for the insurance of patient safety. With the use of FMT in the treatment of recurrent Clostridium difficile infection (RCDI), an investigational new drug (IND) permit is not required, but is strongly encouraged and may ultimately be required.
Some of the available data suggests that the use of fecal microbiota for the restoration of intestinal flora may be an effective therapy in the management of refractory C. difficile infection. According to the study, “Fecal Microbiota Transplant in Patients with Recurrent Clostridium Difficile Infection” published in Deutscher Ärzteverlag GmbH in 2016 concluded that FMT is a safe and effective treatment option for rCDI but FMT is available only in few centers in Germany. Thus clinical effectiveness of this therapy poses opportunities for the human microbiome treatment to grow in the European region.
Germany is anticipated to lead the adoptions of Human microbiome across the Europe region through the forecast period. Human microbiome is an emerging field in the country and the developments are being conducted widely in the country. The genome-wide association analysis study carried out in Germany was published in 2016. The study identifies variation in vitamin D receptor and other host factors influence the gut microbiota.
In addition, Germany invests considerably for innovation and development of new technologies and procedures. For instance, in April 2017, the German Science Council, has approved 53 million euros in funding for an Institute of Microbiota and Cancer Research in Tübingen. Thus, considering and analyzing the above mentioned factors, the human microbiome market is likely to grow with a significant growth rate in the coming future.
EUROPE HUMAN MICROBIOME- MARKET SEGMENTATION
By Product
• Probiotics
• Foods
• Prebiotics
• Medical Foods
• Diagnostic Device
• Drugs
• Supplements
EUROPE HUMAN MICROBIOME- MARKET SEGMENTATION
By Disease
• Obesity
• Diabetes
• Autoimmune Disorders
• Cancer
• Mental Disorders
• Others
EUROPE HUMAN MICROBIOME- MARKET SEGMENTATION
By Application
• Therapeutics
• Diagnostics
By Country
• U.S.
• Canada
• Mexico
Companies Mentioned
• Enterome
• MicroBiome Therapeutics, LLC
• Rebiotix Inc.
• Yakult Honsha Co., Ltd.
• Osel Inc.
• Vedanta Biosciences, Inc.
• Metabiomics Corporate
• Synthetic Biologics, Inc.
• DuPont
• BiomX Ltd.
The growth of the market is driven by the factors such alarming rise in non-communicable diseases (NCDS), rising efforts in the development of human microbiome based therapies and developments in genomics and sequencing techniques. Whereas, rigorous government regulations for advanced therapies and limited understanding is likely to have a negative impact on the growth of the market in the coming years.
Fecal microbiota transplantation (FMT) has developed as an effective treatment for C. difficile infection (CDI) refractory towards antibiotic therapy. The microbiota have important roles in the function of gastrointestinal tract and other aspects of human physiology, there is also growing interest in studying FMT for other clinical indications. The US Food and Drug Administration (FDA) has classified human stool as a biological agent and determined that its use in fecal microbiota transplantation (FMT) therapy and other research are regulated for the insurance of patient safety. With the use of FMT in the treatment of recurrent Clostridium difficile infection (RCDI), an investigational new drug (IND) permit is not required, but is strongly encouraged and may ultimately be required.
Some of the available data suggests that the use of fecal microbiota for the restoration of intestinal flora may be an effective therapy in the management of refractory C. difficile infection. According to the study, “Fecal Microbiota Transplant in Patients with Recurrent Clostridium Difficile Infection” published in Deutscher Ärzteverlag GmbH in 2016 concluded that FMT is a safe and effective treatment option for rCDI but FMT is available only in few centers in Germany. Thus clinical effectiveness of this therapy poses opportunities for the human microbiome treatment to grow in the European region.
Germany is anticipated to lead the adoptions of Human microbiome across the Europe region through the forecast period. Human microbiome is an emerging field in the country and the developments are being conducted widely in the country. The genome-wide association analysis study carried out in Germany was published in 2016. The study identifies variation in vitamin D receptor and other host factors influence the gut microbiota.
In addition, Germany invests considerably for innovation and development of new technologies and procedures. For instance, in April 2017, the German Science Council, has approved 53 million euros in funding for an Institute of Microbiota and Cancer Research in Tübingen. Thus, considering and analyzing the above mentioned factors, the human microbiome market is likely to grow with a significant growth rate in the coming future.
Exhibit: Rest Of Europe Human microbiome Market Revenue and Forecasts to 2027 (US$ Bn)
EUROPE HUMAN MICROBIOME- MARKET SEGMENTATION
By Product
• Probiotics
• Foods
• Prebiotics
• Medical Foods
• Diagnostic Device
• Drugs
• Supplements
EUROPE HUMAN MICROBIOME- MARKET SEGMENTATION
By Disease
• Obesity
• Diabetes
• Autoimmune Disorders
• Cancer
• Mental Disorders
• Others
EUROPE HUMAN MICROBIOME- MARKET SEGMENTATION
By Application
• Therapeutics
• Diagnostics
By Country
• U.S.
• Canada
• Mexico
Companies Mentioned
• Enterome
• MicroBiome Therapeutics, LLC
• Rebiotix Inc.
• Yakult Honsha Co., Ltd.
• Osel Inc.
• Vedanta Biosciences, Inc.
• Metabiomics Corporate
• Synthetic Biologics, Inc.
• DuPont
• BiomX Ltd.
PART 1. iNTRODUCTION
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
PART 2. Europe Human microbiome Market – Key takeaways
PART 3. Europe Human microbiome market – market landscape
3.1 overview
3.2 market segmentation
3.2.1 Europe Human Microbiome Market – By Product
3.2.2 Europe Human Microbiome Market – By Disease
3.2.3 Europe Human Microbiome Market – By Application
3.2.4 Europe Human Microbiome Market – By Country
3.3 PEST Analysis
3.3.1 Europe – PEST Analysis
PART 4. Europe HUMAN MICROBIOME market- Key Market Dynamics
4.1 Key Market Drivers
4.1.1 Alarming Rise In Non-Communicable Diseases (NCDs)
4.1.2 Rising Efforts in the Development of Human Microbiome based Therapies
4.1.3 Developments in Genomics and Sequencing techniques
4.2 Key Market Restraints
4.2.1 Rigorous Government Regulations for Advanced Therapies
4.2.2 Limited Understanding Restricts the Growth of Market
4.3 Key Market Opportunities
4.3.1 Increasing Acceptance of Faecal Microbiota Transplantation
4.4 future Trends
4.4.1 Recent Advances in Human Microbiome Drug Discovery
4.5 Impact analysis
PART 5. Human microbiome market – Europe Analysis
5.1 Europe Human microbiome market Revenue Forecasts and Analysis
5.3 Market positioning
5.4 PERFORMANCE OF KEY PLAYERS
Enterome
Yakult Honsha Co., Ltd.
5.5 expert opinions
PART 6. Europe Human microbiome market Analysis – By Product
6.1 Overview
6.2 EUROPE Human microbiome MARKET, BY product, 2017 & 2025 (%)
6.3 Europe Human microbiome market Revenue And Forecasts to 2025, By Product (US$ Mn)
6.4 FOODS Market
6.4.1 Overview
6.4.2 Europe Foods Market Revenue and Forecasts to 2025 (US$ Mn)
6.5 Medical food Market
6.5.1 Overview
6.5.2 Europe Medical Food Market Revenue and Forecasts to 2025 (US$ Mn)
6.6 probiotics Market
6.6.1 Overview
6.6.2 Europe Probiotics Market Revenue and Forecasts to 2025 (US$ Mn)
6.7 prebiotics Market
6.7.1 Overview
6.7.2 Europe Prebiotics Market Revenue and Forecasts to 2025 (US$ Mn)
6.8 drugs Market
6.8.1 Overview
6.8.2 Europe Drugs Market Revenue and Forecasts to 2025 (US$ Mn)
6.9 DIAGNOSTIC DEVICES Market
6.9.1 Overview
6.9.2 Europe Diagnostic Devices Market Revenue and Forecasts to 2025 (US$ Mn)
6.10 SUPPLEMENTS Market
6.10.1 Overview
6.10.2 Europe Supplements Market Revenue and Forecasts to 2025 (US$ Mn)
PART 7. Europe human microbiome market Analysis – By disease
7.1 Overview
7.2 EUROPE Human microbiome MARKET, BY disease, 2017 & 2025 (%)
7.3 Europe Human microbiome market Revenue And Forecasts to 2025, By disease (US$ Mn)
7.4 diabetes Market
7.4.1 Overview
7.4.2 Europe Diabetes Market Revenue and Forecasts to 2025 (US$ Mn)
7.5 CANCER Market
7.5.1 Overview
7.5.2 Europe Cancer Market Revenue and Forecasts to 2025 (US$ Mn)
7.6 AUTOIMMUNE DISORDERS Market
7.6.1 Overview
7.6.2 Europe Autoimmune Disorders Market Revenue and Forecasts to 2025 (US$ Mn)
7.7 OBESITY Market
7.7.1 Overview
7.7.2 Europe Obesity Market Revenue and Forecasts to 2025 (US$ Mn)
7.8 MENTAL DISORDERS Market
7.8.1 Overview
7.8.2 Europe Mental Disorders Market Revenue and Forecasts to 2025 (US$ Mn)
7.9 Others Market
7.9.1 Overview
7.9.2 Europe Others Market Revenue and Forecasts to 2025 (US$ Mn)
PART 8. Europe human microbiome market Analysis – By application
8.1 Overview
8.2 EUROPE Human microbiome MARKET, BY application, 2017 & 2025 (%)
8.3 Europe Human microbiome market Revenue And Forecasts to 2025, By Application (US$ Mn)
8.4 Diagnostics Market
8.4.1 Overview
8.4.2 Europe Diagnostics Market Revenue and Forecasts to 2025 (US$ Mn)
8.5 therapeutics Market
8.5.1 Overview
8.5.2 Europe Therapeutics Market Revenue and Forecasts to 2025 (US$ Mn)
PART 9. Europe Human microbiome market Revenue and Forecasts to 2025
9.1 Overview
9.2 Europe Human microbiome market Revenue and Forecasts to 2025 (US$ Mn)
9.3 Europe Human microbiome market Revenue And Forecasts to 2025, By Product (US$ Mn)
9.4 Europe Human microbiome market Revenue And Forecasts to 2025, By disease (US$ Mn)
9.5 Europe Human microbiome market Revenue And Forecasts to 2025, By Application (US$ Mn)
9.6 Europe Human microbiome market Revenue And Forecasts to 2025, By Country (%)
9.7 UK Human microbiome market Revenue and Forecasts to 2025 (US$ Mn)
9.7.1 UK Human Microbiome Market Revenue and Forecasts to 2025 (US$ Mn)
9.7.2 UK Human Microbiome Market Revenue And Forecasts to 2025, By Product (US$ Mn)
9.7.3 UK Human Microbiome Market Revenue And Forecasts to 2025, By Disease (US$ Mn)
9.7.4 UK Human Microbiome Market Revenue And Forecasts to 2025, By Application (US$ Mn)
9.8 Germany Human microbiome market Revenue and Forecasts to 2025 (US$ Mn)
9.8.1 Germany Human Microbiome Market Revenue and Forecasts to 2025 (US$ Mn)
9.8.2 Germany Human Microbiome Market Revenue And Forecasts to 2025, By Product (US$ Mn)
9.8.3 Germany Human Microbiome Market Revenue And Forecasts to 2025, By Disease (US$ Mn)
9.8.4 Germany Human Microbiome Market Revenue And Forecasts to 2025, By Application (US$ Mn)
9.9 France Human microbiome market Revenue and Forecasts to 2025 (US$ Mn)
9.9.1 France Human Microbiome Market Revenue and Forecasts to 2025 (US$ Mn)
9.9.2 France Human Microbiome Market Revenue And Forecasts to 2025, By Product (US$ Mn)
9.9.3 France Human Microbiome Market Revenue And Forecasts to 2025, By Disease (US$ Mn)
9.9.4 France Human Microbiome Market Revenue And Forecasts to 2025, By Application (US$ Mn)
PART 10. Human Microbiome Market –Industry Landscape
10.1 Overview
10.2 Growth Strategies in the Human Microbiome Market, 2015-2018
10.3 Organic Growth Strategies
10.3.1 Overview
10.3.2 Product Launch & Approvals
10.3.3 Expansion
10.3.4 Patent and license
10.4 Inorganic Growth Strategies
10.4.1 Overview
10.4.2 Acquisitions
10.4.3 Partnerships, Collaborations & Agreements
10.4.4 Joint Ventures
PART 11. Human microbiome Market–Key company profiles
11.1 ENTEROME
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Financial Overview
11.1.4 Product Portfolio
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 MICROBIOME THERAPEUTICS, LLC
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Financial Information
11.2.4 Product Portfolio
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Rebiotix Inc.
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Financial Overview
11.3.4 Product Portfolio
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Yakult Honsha Co., Ltd.
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Financial Overview
11.4.4 Product Portfolio
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Osel Inc.
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Financial Overview
11.5.4 Product Portfolio
11.5.5 Swot Analysis
11.5.6 Key Developments
11.6 Vedanta Biosciences, Inc.
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Financial Information
11.6.4 Product Portfolio
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Metabiomics Corporate
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Financial Overview
11.7.4 Product Portfolio
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Synthetic Biologics, Inc.
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Financial Information
11.8.4 Product Portfolio
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 DuPont
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Financial Overview
11.9.4 Product Portfolio
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 BiomX
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Financial Information
11.10.4 Product Portfolio
11.10.5 SWOT Analysis
11.10.6 Key Developments
PART 12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms
12.3 Methodology
12.3.1 Coverage
12.3.2 Secondary Research
12.3.3 Primary Research
LIST OF TABLES
TABLE 1. Europe Human microbiome market Revenue And Forecasts to 2025, By product (US$ Mn)
TABLE 2. Europe Human microbiome market Revenue And Forecasts to 2025, By disease (US$ Mn)
TABLE 3. Europe Human microbiome market Revenue And Forecasts to 2025, By application (US$ Mn)
TABLE 4. Europe Human microbiome market Revenue And Forecasts to 2025, By product (US$ Mn)
TABLE 5. Europe Human microbiome market Revenue And Forecasts to 2025, By disease (US$ Mn)
TABLE 6. Europe Human microbiome market Revenue And Forecasts to 2025, By application (US$ Mn)
TABLE 7. UK Human microbiome market Revenue And Forecasts to 2025, By Product (US$ Mn)
TABLE 8. UK Human microbiome market Revenue And Forecasts to 2025, By disease (US$ Mn)
TABLE 9. UK Human microbiome market Revenue And Forecasts to 2025, By application (US$ Mn)
TABLE 10. Germany Human microbiome market Revenue And Forecasts to 2025, By Product (US$ Mn)
TABLE 11. Germany Human microbiome market Revenue And Forecasts to 2025, By disease (US$ Mn)
TABLE 12. Germany Human microbiome market Revenue And Forecasts to 2025, By application (US$ Mn)
TABLE 13. France Human microbiome market Revenue And Forecasts to 2025, By Product (US$ Mn)
TABLE 14. France Human microbiome market Revenue And Forecasts to 2025, By disease (US$ Mn)
TABLE 15. France Human microbiome market Revenue And Forecasts to 2025, By application (US$ Mn)
TABLE 16. Recent Product Launches & Approvals in the Human Microbiome Market
TABLE 17. Recent EXPANSIONS in the Human Microbiome Market
TABLE 18. Patent and License Organic Growth Strategies in the Human Microbiome Market
TABLE 19. Recent Acquisitions in the Human Microbiome market
TABLE 20. Recent Partnerships & Collaborations in the Human Microbiome market
TABLE 21. Joint Ventures inOrganic Growth Strategies in the Human Microbiome Market
TABLE 22. Glossary of Terms, Human microbiome market
LIST OF FIGURES
FIGURE 1. UK Human microbiome market, Revenue (US$ Mn), By country 2018 & 2025
FIGURE 2. Europe human microbiome Market By product, Market Share (%), 2017
FIGURE 3. Europe Human microbiome Market By disease, Market Share (%), 2017
FIGURE 4. Europe Human microbiome Market By application, Market Share (%), 2017
FIGURE 5. Human microbiome market Segmentation
FIGURE 6. Europe PEST Analysis
FIGURE 7. human microbiome market impact analysis of drivers & Restraints
FIGURE 8. Europe Human microbiome market – Revenue Forecasts and Analysis – 2017- 2025
FIGURE 9. Europe Human microbiome market, By Product, 2017 & 2025 (%)
FIGURE 10. Europe foods Market Revenue and Forecasts to 2025 (US$ Mn)
FIGURE 11. Europe Medical Food Market Revenue and Forecasts to 2025 (US$ Mn)
FIGURE 12. Europe Probiotics Market Revenue and Forecasts to 2025 (US$ Mn)
FIGURE 13. Europe Prebiotics Market Revenue and Forecasts to 2025 (US$ Mn)
FIGURE 14. Europe drugs Market Revenue and Forecasts to 2025 (US$ Mn)
FIGURE 15. Europe DIAGNOSTIC DEVICES Market Revenue and Forecasts to 2025 (US$ Mn)
FIGURE 16. Europe SUPPLEMENTS Market Revenue and Forecasts to 2025 (US$ Mn)
FIGURE 17. Europe Human microbiome market By disease, 2017 & 2025 (%)
FIGURE 18. Europe Diabetes Market Revenue and Forecasts to 2025 (US$ Mn)
FIGURE 19. Europe Cancer Market Revenue and Forecasts to 2025 (US$ Mn)
FIGURE 20. Europe Autoimmune Diseases Market Revenue and Forecasts to 2025 (US$ Mn)
FIGURE 21. Europe Obesity Market Revenue and Forecasts to 2025 (US$ Mn)
FIGURE 22. Europe MENTAL DISORDERS Market Revenue and Forecasts to 2025 (US$ Mn)
FIGURE 23. Europe Others Market Revenue and Forecasts to 2025 (US$ Mn)
FIGURE 24. Europe Human microbiome market By application, 2017 & 2025 (%)
FIGURE 25. Europe diagnostics Market Revenue and Forecasts to 2025 (US$ Mn)
FIGURE 26. Europe Therapeutics Market Revenue and Forecasts to 2025 (US$ Mn)
FIGURE 27. Europe Human microbiome market REVENUE overview, by Country, 2017 (US$ MN)
FIGURE 28. Europe Human microbiome Market Revenue and Forecasts to 2025 (US$ Mn)
FIGURE 29. Europe Human microbiome market Revenue And Forecasts to 2025, By Country (%)
FIGURE 30. UK Human microbiome market Revenue and Forecasts to 2025 (US$ Mn)
FIGURE 31. Germany Human microbiome market Revenue and Forecasts to 2025 (US$ Mn)
FIGURE 32. France Human microbiome market Revenue and Forecasts to 2025 (US$ Mn)
FIGURE 33. Growth Strategies in the Human Microbiome Market, 2015-2018
FIGURE 34. Organic Growth Strategies in the Human Microbiome Market, 2015-2018
FIGURE 35. Inorganic Growth Strategies in the human microbiome Market, 2015-2018
The List of Companies
- Enterome
- MicroBiome Therapeutics, LLC
- Rebiotix Inc.
- Yakult Honsha Co., Ltd.
- Osel Inc.
- Vedanta Biosciences, Inc.
- Metabiomics Corporate
- Synthetic Biologics, Inc.
- DuPont
- BiomX Ltd.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the human microbiome market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global human microbiome market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.